Cargando…

The risk of lymph node metastasis makes it unsafe to expand the conventional indications for endoscopic treatment of T1 colorectal cancer: A retrospective study of 428 patients

Though endoscopic treatment is an option for T1 colorectal cancer (CRC), the optimal indications and long-term outcomes of this strategy need to be validated. Therefore, the aim of this study is to investigate long-term outcomes of endoscopy versus surgery and optimal indications for endoscopic trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Bun, Kim, Eun Hye, Park, Soo Jung, Cheon, Jae Hee, Kim, Tae Il, Kim, Won Ho, Kim, Hoguen, Hong, Sung Pil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5402546/
https://www.ncbi.nlm.nih.gov/pubmed/27631203
http://dx.doi.org/10.1097/MD.0000000000004373
_version_ 1783231241812705280
author Kim, Bun
Kim, Eun Hye
Park, Soo Jung
Cheon, Jae Hee
Kim, Tae Il
Kim, Won Ho
Kim, Hoguen
Hong, Sung Pil
author_facet Kim, Bun
Kim, Eun Hye
Park, Soo Jung
Cheon, Jae Hee
Kim, Tae Il
Kim, Won Ho
Kim, Hoguen
Hong, Sung Pil
author_sort Kim, Bun
collection PubMed
description Though endoscopic treatment is an option for T1 colorectal cancer (CRC), the optimal indications and long-term outcomes of this strategy need to be validated. Therefore, the aim of this study is to investigate long-term outcomes of endoscopy versus surgery and optimal indications for endoscopic treatment of T1 CRC. This retrospective study included 428 T1 CRC patients treated with initial endoscopy (n = 224) or surgery (n = 204) at Severance Hospital between 2005 and 2012. Patients were subdivided into 4 groups according to conventional indications (CIs) for endoscopic treatment: negative lateral/vertical margins; submucosal invasion depth within 1000 μm; no lymphovascular invasion (LVI); well or moderately differentiated. For prognosis evaluation, short-term outcomes (resection margin and complications) and long-term outcomes (recurrence and cancer-specific mortality) were evaluated. Endoscopic treatment achieved en bloc resection in 86.6% of 224 patients. Recurrence and mortality did not differ between the endoscopy and surgery groups with or without CIs. For patients with CIs, although 80 patients were treated endoscopically with 1 (1.3%) recurrence and 0 mortality, 75 patients were treated surgically with 2 (2.7%) recurrence and 1 (1.3%) mortality. Multivariate analysis revealed that LVI positivity and poorly differentiated histology were independently associated with lymph node metastasis (LNM; P < 0.001 and P = 0.001, respectively). To determine whether the depth of submucosal invasion among criteria of CIs could be extended for endoscopic treatment, LNM was analyzed by extending the depth of submucosal invasion. There was no LNM in 155 patients within conventional indication. When the depth of submucosal invasion was extended up to 1500 μm, LNM was occurred (1/197 patient [0.5%]). In addition, when the depth of submucosal invasion was extended up to 2000 μm, LNM was increased (4/271 patient [1.5%]). Endoscopic treatment is safe, effective, and is associated with favorable long-term outcomes compared to surgery for initial treatment of T1 CRC patients with CIs. However, the risk of LNM makes it unsafe to extend the CIs for endoscopic therapy in these patients.
format Online
Article
Text
id pubmed-5402546
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-54025462017-04-27 The risk of lymph node metastasis makes it unsafe to expand the conventional indications for endoscopic treatment of T1 colorectal cancer: A retrospective study of 428 patients Kim, Bun Kim, Eun Hye Park, Soo Jung Cheon, Jae Hee Kim, Tae Il Kim, Won Ho Kim, Hoguen Hong, Sung Pil Medicine (Baltimore) 4500 Though endoscopic treatment is an option for T1 colorectal cancer (CRC), the optimal indications and long-term outcomes of this strategy need to be validated. Therefore, the aim of this study is to investigate long-term outcomes of endoscopy versus surgery and optimal indications for endoscopic treatment of T1 CRC. This retrospective study included 428 T1 CRC patients treated with initial endoscopy (n = 224) or surgery (n = 204) at Severance Hospital between 2005 and 2012. Patients were subdivided into 4 groups according to conventional indications (CIs) for endoscopic treatment: negative lateral/vertical margins; submucosal invasion depth within 1000 μm; no lymphovascular invasion (LVI); well or moderately differentiated. For prognosis evaluation, short-term outcomes (resection margin and complications) and long-term outcomes (recurrence and cancer-specific mortality) were evaluated. Endoscopic treatment achieved en bloc resection in 86.6% of 224 patients. Recurrence and mortality did not differ between the endoscopy and surgery groups with or without CIs. For patients with CIs, although 80 patients were treated endoscopically with 1 (1.3%) recurrence and 0 mortality, 75 patients were treated surgically with 2 (2.7%) recurrence and 1 (1.3%) mortality. Multivariate analysis revealed that LVI positivity and poorly differentiated histology were independently associated with lymph node metastasis (LNM; P < 0.001 and P = 0.001, respectively). To determine whether the depth of submucosal invasion among criteria of CIs could be extended for endoscopic treatment, LNM was analyzed by extending the depth of submucosal invasion. There was no LNM in 155 patients within conventional indication. When the depth of submucosal invasion was extended up to 1500 μm, LNM was occurred (1/197 patient [0.5%]). In addition, when the depth of submucosal invasion was extended up to 2000 μm, LNM was increased (4/271 patient [1.5%]). Endoscopic treatment is safe, effective, and is associated with favorable long-term outcomes compared to surgery for initial treatment of T1 CRC patients with CIs. However, the risk of LNM makes it unsafe to extend the CIs for endoscopic therapy in these patients. Wolters Kluwer Health 2016-09-16 /pmc/articles/PMC5402546/ /pubmed/27631203 http://dx.doi.org/10.1097/MD.0000000000004373 Text en Copyright © 2016 the Author(s). Published by Wolters Kluwer Health, Inc. All rights reserved. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0, where it is permissible to download, share and reproduce the work in any medium, provided it is properly cited. The work cannot be changed in any way or used commercially. http://creativecommons.org/licenses/by-nc-nd/4.0
spellingShingle 4500
Kim, Bun
Kim, Eun Hye
Park, Soo Jung
Cheon, Jae Hee
Kim, Tae Il
Kim, Won Ho
Kim, Hoguen
Hong, Sung Pil
The risk of lymph node metastasis makes it unsafe to expand the conventional indications for endoscopic treatment of T1 colorectal cancer: A retrospective study of 428 patients
title The risk of lymph node metastasis makes it unsafe to expand the conventional indications for endoscopic treatment of T1 colorectal cancer: A retrospective study of 428 patients
title_full The risk of lymph node metastasis makes it unsafe to expand the conventional indications for endoscopic treatment of T1 colorectal cancer: A retrospective study of 428 patients
title_fullStr The risk of lymph node metastasis makes it unsafe to expand the conventional indications for endoscopic treatment of T1 colorectal cancer: A retrospective study of 428 patients
title_full_unstemmed The risk of lymph node metastasis makes it unsafe to expand the conventional indications for endoscopic treatment of T1 colorectal cancer: A retrospective study of 428 patients
title_short The risk of lymph node metastasis makes it unsafe to expand the conventional indications for endoscopic treatment of T1 colorectal cancer: A retrospective study of 428 patients
title_sort risk of lymph node metastasis makes it unsafe to expand the conventional indications for endoscopic treatment of t1 colorectal cancer: a retrospective study of 428 patients
topic 4500
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5402546/
https://www.ncbi.nlm.nih.gov/pubmed/27631203
http://dx.doi.org/10.1097/MD.0000000000004373
work_keys_str_mv AT kimbun theriskoflymphnodemetastasismakesitunsafetoexpandtheconventionalindicationsforendoscopictreatmentoft1colorectalcanceraretrospectivestudyof428patients
AT kimeunhye theriskoflymphnodemetastasismakesitunsafetoexpandtheconventionalindicationsforendoscopictreatmentoft1colorectalcanceraretrospectivestudyof428patients
AT parksoojung theriskoflymphnodemetastasismakesitunsafetoexpandtheconventionalindicationsforendoscopictreatmentoft1colorectalcanceraretrospectivestudyof428patients
AT cheonjaehee theriskoflymphnodemetastasismakesitunsafetoexpandtheconventionalindicationsforendoscopictreatmentoft1colorectalcanceraretrospectivestudyof428patients
AT kimtaeil theriskoflymphnodemetastasismakesitunsafetoexpandtheconventionalindicationsforendoscopictreatmentoft1colorectalcanceraretrospectivestudyof428patients
AT kimwonho theriskoflymphnodemetastasismakesitunsafetoexpandtheconventionalindicationsforendoscopictreatmentoft1colorectalcanceraretrospectivestudyof428patients
AT kimhoguen theriskoflymphnodemetastasismakesitunsafetoexpandtheconventionalindicationsforendoscopictreatmentoft1colorectalcanceraretrospectivestudyof428patients
AT hongsungpil theriskoflymphnodemetastasismakesitunsafetoexpandtheconventionalindicationsforendoscopictreatmentoft1colorectalcanceraretrospectivestudyof428patients
AT kimbun riskoflymphnodemetastasismakesitunsafetoexpandtheconventionalindicationsforendoscopictreatmentoft1colorectalcanceraretrospectivestudyof428patients
AT kimeunhye riskoflymphnodemetastasismakesitunsafetoexpandtheconventionalindicationsforendoscopictreatmentoft1colorectalcanceraretrospectivestudyof428patients
AT parksoojung riskoflymphnodemetastasismakesitunsafetoexpandtheconventionalindicationsforendoscopictreatmentoft1colorectalcanceraretrospectivestudyof428patients
AT cheonjaehee riskoflymphnodemetastasismakesitunsafetoexpandtheconventionalindicationsforendoscopictreatmentoft1colorectalcanceraretrospectivestudyof428patients
AT kimtaeil riskoflymphnodemetastasismakesitunsafetoexpandtheconventionalindicationsforendoscopictreatmentoft1colorectalcanceraretrospectivestudyof428patients
AT kimwonho riskoflymphnodemetastasismakesitunsafetoexpandtheconventionalindicationsforendoscopictreatmentoft1colorectalcanceraretrospectivestudyof428patients
AT kimhoguen riskoflymphnodemetastasismakesitunsafetoexpandtheconventionalindicationsforendoscopictreatmentoft1colorectalcanceraretrospectivestudyof428patients
AT hongsungpil riskoflymphnodemetastasismakesitunsafetoexpandtheconventionalindicationsforendoscopictreatmentoft1colorectalcanceraretrospectivestudyof428patients